PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35114682-1	2022	BACKGROUND: De-escalation therapy omitting anthracycline has been generally adopted for patients with HER2-positive early breast cancer in the adjuvant setting, but not in the neoadjuvant chemotherapy (NAC) setting.	Anthracyclines	43-56	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-106